Prot #CA180399: An Open Label, Randomized (2:1) Phase 2b Study of Dasatinib vs. Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy with 400 mg Imatinib

Project: Research project

Project Details

StatusFinished
Effective start/end date4/8/134/8/19

Funding

  • ICON Clinical Research, LLC (Prot #CA180399)
  • Bristol-Myers Squibb Company (Prot #CA180399)